Axial VC
VC Fund
Axial VC is a VC fund focused on Biotechnology and Health Care. Agency for great inventors
- Total investments:
- 22
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Axial VC invests in
Stages Axial VC invests in
Countries Axial VC invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $4.3M–$17M
- Pre-Seed
- $750k–$6M
- Series A
- $12M–$55M
Investment Focus
Industry
- Biotechnology 16 (73%)
- Health Care 7 (32%)
- Life Science 7 (32%)
- Therapeutics 4 (18%)
- Medical 3 (14%)
Stage
- Seed 10 (45%)
- Pre-Seed 7 (32%)
- Series A 4 (18%)
Country
- United States 17 (77%)
- Switzerland 1 (5%)
- United Kingdom 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Joshua Elkington
Founder and General Partner
|
Founder and General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Stately Bio is the trade-off between measuring cells and keeping them alive. Our patented ML technology measures cell identity, behavior, and maturation—all directly from live-cell, label-free imaging. | $12M / Seed / May 01, 2025 | ||
| AI research assistant for biology. | $1M / Pre-Seed / Oct 28, 2024 | ||
| Insamo offers the discovery of membrane-permeable & orally available cyclic-peptides which lies in its automated process of designing, synthesizing, and testing at an unprecedented scale. | $12M / Seed / Feb 21, 2024 | ||
| Omica turns real-world clinical data into structured training infrastructure for biomedical AI. We partner with hospitals and labs to extract, standardize, and validate multimodal patient data — including notes, pathology, imaging, and genomics. Our pipeline combines automation with clinical oversight to produce longitudinal, de-identified datasetsready for research and model training. Through our platform, Atlas, clients can define cohorts, access structured outputs, and power applications in real-world evidence and predictive modeling. Our data assets are already used by leading AI diagnostics companies and global pharma teams building the next generation of clinical tools. | $1M / Pre-Seed / Feb 16, 2024 | ||
| Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States. | $9M / Seed / Nov 29, 2023 | ||
| Nalu Bio is a biotech company developing CBD (and cannabinoids) through chemistry (not plants), for companies who want pure and safe ingredients that are better for the planet. Ranked as the #1 CBD producer on the “google for ingredients.” Like plant-based meats, Nalu Bio will fundamentally disrupt CBD production with chemistry. Nalu Bio uses 700xless land, 70x less water, and 14x less energy to produce its cannabinoids while ensuring best-in-class purity and quality (0% THC, no chemicals, no pesticides) without the high capital investment costs of hemp extraction and biosynthesis. | $12M / Series A / Feb 28, 2023 | ||
| Infinimmune operates as a biotechnology company. Infinimmune reinvents antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. | $12M / Seed / Dec 06, 2022 | ||
| Meliora Therapeutics is a biotech startup that is developing a machine learning-driven platform to identify the true mechanisms of action of oncology medications. | $11M / Seed / Sep 29, 2022 | ||
| Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $2.5M / Pre-Seed / Sep 01, 2022 | ||
| Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems. | $17M / Seed / Aug 18, 2022 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Axial VC invest in?
Axial VC invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Pre-Seed stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Axial VC's check size?
Axial VC typically joins rounds of $4.3M–$17M at Seed, $750k–$6M at Pre-Seed and $12M–$55M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Axial VC participates in.
How do I contact Axial VC?
Public channels for Axial VC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Axial VC?
The team at Axial VC includes Joshua Elkington (Founder and General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
